Adbry 300 mg/2 mL auto-injectors (tralokinumab-ldrm subcutaneous injection) — Cigna
moderate to severe atopic dermatitis in patients age ≥ 12 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
Initial criteria
- If the patient is initiating therapy, as verified by the absence of claims for Adbry in the past 130 days, approve a one-time override for 3 auto-injectors at retail or 7 auto-injectors at home delivery
Approval duration
30 days (one-time override)